© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 10, 738-740,
May 16, 2001
© 2001 Oxford University Press
NEWS |
Can the Long Road from Bench to Bedside Be Shortened?
In 2001, it is estimated that 1,268,000 people in the United States alone will be diagnosed with cancer. Many of these people will seek what they consider "the latest and greatest" in cancer treatment, demanding the state of the art from their health care providers.
The good news: according to the Pharmaceutical Research and Manufacturers of America, there are 402 medicines in the pipeline for cancer. The bad news: many of these therapies still need to be rigorously tested in clinical trials, the results of which may not be available for decades.
The rationale for clinical trials is clear. As one of the final stages of a long and careful cancer research process, trials determine if promising approaches to cancer prevention, diagnosis, and treatment are safe and effective in humans. Clinical trial results provide the benchmark for which procedures or drugs are moved from an "experimental"
The Waiting Game
Proposing Change